☆ 4.6 Article

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Fabrice Andre et al.

Summary: This article provides updated recommendations on the appropriate use of breast cancer biomarker assay results in guiding adjuvant endocrine and chemotherapy decisions for early-stage breast cancer. Based on the latest literature and expert consensus, specific biomarker assay results can be used to guide treatment decisions for patients who meet certain criteria. However, other factors such as disease stage, comorbidities, and patient preferences should also be considered.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

Torsten O. Nielsen et al.

Summary: Ki67 immunohistochemistry (IHC) is commonly used in breast cancer as a proliferation marker, but its analytical validity has been questioned. The International Ki67 in Breast Cancer Working Group (IKWG) recommends careful preanalytical handling, adoption of a standardized visual scoring method, and participation in quality assurance and quality control programs. Clinical utility of Ki67 IHC in breast cancer care is currently limited to prognosis assessment in stage I or II breast cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Medicine, General & Internal

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kevin Kalinsky et al.

Summary: The study showed that among premenopausal women with hormone-receptor-positive, HER2-negative breast cancer and one to three positive lymph nodes with a recurrence score of 25 or lower, the addition of chemotherapy to endocrine therapy led to longer invasive disease-free survival and distant relapse-free survival compared to endocrine therapy alone. However, postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy in terms of invasive disease-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart et al.

Summary: The MINDACT trial demonstrated that patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy had excellent 5-year distant metastasis-free survival. The long-term follow-up results, including exploratory analysis by age, further support the use of genomic testing in identifying patients who can forgo chemotherapy. Chemotherapy showed different effects on distant metastasis-free survival based on age and nodal status, especially in hormone receptor-positive, HER2-negative disease.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study

Balazs Acs et al.

Summary: The study compared ER, PR, HER2, Ki67, and grade scores among pathology departments in Sweden, revealing limited variability in ER, PR, and HER2 testing but high variability in grading and Ki67 assessment, indicating a need for new technologies. Outlier labs affected endocrine and anti-HER2 treatment rates, emphasizing the importance of monitoring biomarker expression and treatment rates to improve clinical management of breast cancer.

CANCERS (2021)

添加到收藏夹

Article Oncology

Prosigna test in breast cancer: real-life experience

D. Hequet et al.

Summary: Using the Prosigna test to guide adjuvant therapy decisions can effectively reduce chemotherapy indications for breast cancer patients, resulting in cost savings.

BREAST CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Olivia Pagani et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer

Philip D. Poorvu et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

Valerie E. Crolley et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

添加到收藏夹

Article Medicine, General & Internal

The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer

Hirah Rizki et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2020)

添加到收藏夹

Review Oncology

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

A. Matikas et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Cardoso et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer

Christine Lundgren et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

Aranzazu Fernandez-Martinez et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary

Ian Krop et al.

JOURNAL OF ONCOLOGY PRACTICE (2017)

添加到收藏夹

Article Oncology

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

Hege O. Ohnstad et al.

BREAST CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation

Francisco J. Candido dos Reis et al.

BREAST CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Ivana Sestak et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

M. Gnant et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A. Goldhirsch et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Mitch Dowsett et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

Berit Maria Mueller et al.

PLOS ONE (2013)

添加到收藏夹

Article Medicine, General & Internal

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

K. Albain et al.

LANCET (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt et al.

NATURE (2012)

添加到收藏夹

Article Oncology

PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Gordon C. Wishart et al.

BREAST CANCER RESEARCH (2010)

添加到收藏夹

Article Oncology

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Joel S. Parker et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Review Medicine, General & Internal

MOLECULAR ORIGINS OF CANCER Gene-Expression Signatures in Breast Cancer

Christos Sotiriou et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Multidisciplinary Sciences

Repeated observation of breast tumor subtypes in independent gene expression data sets

T Sorlie et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular portraits of human breast tumours

CM Perou et al.

NATURE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.